文献速递生殖医学

低抗苗勒管激素水平不是IVF/ICSI早期妊娠丢失的危险因素

Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment.
PubMed 文献 · Hum Reprod · 2020-01-01

该回顾性队列研究纳入2012-2016年芬兰赫尔辛基大学医院1383例首次取卵行IVF/ICSI的女性,分析低(<1.0 μg/L)或中等偏低(1.0-1.9 μg/L)血清AMH与早期妊娠丢失的关系。结果显示,与正常AMH(≥2.0 μg/L)相比,低或中等偏低AMH不增加流产、未着床妊娠丢失或总体早期妊娠丢失风险,但低/中等偏低AMH女性累积妊娠率和累积活产率较低。

要点

  • 低或中等偏低AMH不增加IVF/ICSI后流产、未着床妊娠丢失或早期妊娠丢失风险。
  • 低AMH女性累积妊娠率和累积活产率较低,因获卵数和胚胎数较少。
  • 咨询时可告知低AMH患者早期妊娠丢失风险未升高。

核心结论

  • 低或中等偏低血清AMH水平与IVF/ICSI治疗中流产、未着床妊娠丢失或总体早期妊娠丢失率无关。

研究设计与样本

  • 回顾性队列研究,纳入2012-2016年芬兰赫尔辛基大学医院1383例首次取卵行IVF/ICSI的女性,所有新鲜(n=1315)和冻融(n=1418)胚胎移植周期于2018年8月前完成。
  • AMH在IVF/ICSI刺激前12个月内测量。

主要发现

  • 1123例妊娠中,285例(25.4%)为未着床妊娠丢失,143例(12.7%)为流产。
  • 每次胚胎移植的活产率为24.6%(673/2733)。
  • 低AMH(<1.0 μg/L)与正常AMH(≥2.0 μg/L)相比,流产 vs 活产的调整RR为0.70(95%CI 0.42-1.17),未着床妊娠丢失 vs 活产的调整RR为0.90(95%CI 0.65-1.23)。
  • 中等偏低AMH(1.0-1.9 μg/L)与正常AMH相比,流产 vs 活产的调整RR为1.00(95%CI 0.68-1.49),未着床妊娠丢失 vs 活产的调整RR为1.09(95%CI 0.85-1.41)。
  • 低AMH、中等偏低AMH和正常AMH女性的累积妊娠率/累积活产率分别为50.6/34.0%、59.0/36.3%和68.3/49.2%。

关键数值与推荐

  • AMH分组:低<1.0 μg/L(235例,17.0%),中等偏低1.0-1.9 μg/L(278例,20.1%),正常≥2.0 μg/L(870例,62.9%)。
  • 低AMH与正常AMH相比,早期妊娠丢失 vs 活产的调整RR为0.86(95%CI 0.68-1.10)。
  • 中等偏低AMH与正常AMH相比,早期妊娠丢失 vs 活产的调整RR为1.01(95%CI 0.86-1.27)。
  • 调整的混杂因素包括女性年龄、超重、吸烟、子宫内膜异位症病史和基础疾病。

临床怎么用

  • 低或中等偏低AMH女性在IVF/ICSI治疗中早期妊娠丢失风险未增加,可用于咨询安抚。
  • 低AMH女性累积活产率较低主要与获卵数和胚胎数较少有关,应据此评估整体治疗效果。

局限性

  • 低AMH组流产数量较少,研究效能受限。
  • 真实临床环境限制了对所有导致选择偏倚的因素的控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is a low (<1.0 μg/L) or moderately low (1.0-1.9 μg/L) serum anti-Müllerian hormone (AMH) level a risk factor for early pregnancy loss in IVF/ICSI with a fresh or frozen-thawed embryo transfer (ET)? SUMMARY ANSWER: A low or moderately low serum AMH level does not associate with miscarriage, non-visualized pregnancy loss or overall early pregnancy loss rate in the IVF/ICSI treatment. WHAT IS KNOWN ALREADY: Low AMH predicts poor ovarian response and small oocyte yield in IVF/ICSI treatment, but its value in the evaluation of live birth rate (LBR) is modest. Little is known about the risk of early pregnancy loss in ART among women with low AMH. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study on 1383 women undergoing their first oocyte retrieval for IVF/ICSI in Helsinki University Hospital in Helsinki, Finland, between 2012 and 2016, with all associated fresh (n = 1315) and frozen-thawed (n = 1418) ET cycles finished by August 2018. AMH was measured within 12 months before the IVF/ICSI stimulation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of all the women, 235 (17.0%) had low (<1.0 μg/L), 278 (20.1%) had moderately low (1.0-1.9 μg/L) and 870 (62.9%) had normal (≥2.0 μg/L) AMH. The primary outcomes were miscarriage, non-visualized pregnancy loss and early pregnancy loss (miscarriage and non-visualized pregnancy loss combined) after fresh or frozen-thawed ET. The impact of AMH on these outcomes was calculated in three populations: among all women who became pregnant, among women with AMH ≤6.0 μg/L and in a population weighted by the inverse probability of becoming pregnant (inverse probability weighting, IPW). The impact of AMH was also assessed on the secondary outcomes, cumulative pregnancy rate (cPR) and cumulative live birth rate (cLBR) across all ET cycles in the woman's first IVF/ICSI. Potential confounders (the woman's age, overweight, smoking, history of endometriosis and underlying medical conditions) adjusted the final results. MAIN RESULTS AND THE ROLE OF CHANCE: Of 1123 pregnancies, 285 (25.4%) ended in non-visualized pregnancy loss and 143 (12.7%) in miscarriage. The LBR was 24.6% per ET (673/2733). Low or moderately low AMH, compared with normal AMH, did not associate with miscarriage or non-visualized pregnancy loss in analyses among all women who became pregnant (adjusted relative risk (RR) for miscarriage vs live birth, 0.70 and 95% CI 0.42-1.17 in low AMH and adjusted RR, 1.00 and 95% CI, 0.68-1.49 in moderately low AMH; adjusted RR for non-visualized pregnancy loss vs live birth, 0.90 and 95% CI, 0.65-1.23 in low AMH and adjusted RR, 1.09 and 95% CI 0.85-1.41 in moderately low AMH), nor did low or moderately low AMH associate with the overall early pregnancy loss rate (adjusted RR for early pregnancy loss vs live birth, 0.86 and 95% CI, 0.68-1.10 in low AMH and adjusted RR, 1.01 and 95% CI, 0.86-1.27 in moderately low AMH). Results remained similar after restricting the analysis to women with AMH ≤6.0 μg/L. Women with low or moderately low AMH had fewer pregnancies and live births than women with normal AMH in their first IVF/ICSI (cPR/cLBR in women with low AMH 50.6/34.0%, moderately low AMH 59.0/36.3% and normal AMH 68.3/49.2%). When the lower probability for pregnancy was considered by using IPW, women with low or moderately low AMH did not have a higher risk for miscarriage, non-visualized pregnancy loss or overall early pregnancy loss compared with women with normal AMH. LIMITATIONS, REASONS FOR CAUTION: The number of miscarriages in women with low AMH was moderately small, limiting the power of the study. The real-world clinical setting of the study restricted the ability to control for all factors causing selection bias. WIDER IMPLICATIONS OF THE FINDINGS: The cLBR was higher among women with normal AMH than among women with low or moderately low AMH in their first IVF/ICSI treatment because these women had more oocytes and embryos. Women with low or moderately low AMH did not have an increased risk for early pregnancy loss. This information is reassuring for couples and useful in counseling. These results are also valuable when assessing the overall effectiveness of IVF/ICSI treatment. STUDY FUNDING/COMPETING INTEREST(S): Research funds from Helsinki University Hospital (no. TYH2018232), Hyvinkää Hospital (no. M3080TUT18) and the Emil Aaltonen Foundation for P.P. Grants from the Paulo Foundation and the Finnish Medical Foundation for H.H. The authors report no conflicts of interest. TRIAL REGISTRATION NUMBER: HUS/138/2017.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Peuranpää P, Hautamäki H, Halttunen-Nieminen M, et al. Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment. Hum Reprod. 2020. PMID: 32219343. doi:10.1093/humrep/deaa008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。